Literature summary for 7.2.2.10 extracted from

Ahmad, S.; Ahmad, A.; Dremina, E.S.; Sharov, V.S.; Guo, X.; Jones, T.N.; Loader, J.E.; Tatreau, J.R.; Perraud, A.L.; Schoeneich, C.; Randell, S.H.; White, C.W.
Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression in cystic fibrosis airways: role in oxidant-mediated cell death (2009), Am. J. Respir. Crit. Care Med., 179, 816-826.

Search for more literature for 7.2.2.10

Application

Application	Comment	Organism
medicine	SERCA2 expression and activity are decreased in cycstic fibrosis airway epithelium resulting in enhanced susceptibility to oxidants, reduced SERCA2 expression may alter calcium signalling and apoptosis in cystic fibrosis	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
additional information	SERCA protein expression is decreased by inhibition of cystic fibrosis transmembrane regulator function with the specific cystic fibrosis transmembrane regulator inhibitor CFTRinh172	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
endoplasmic reticulum	-	Homo sapiens	5783	-
sarcoplasmic reticulum	-	Homo sapiens	16529	-

Metals/Ions

Metals/Ions	Comment	Organism	Structure
Ca2+	dependent on	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
16-HBEo cell	-	Homo sapiens	-
airway epithelial cell	CF-41o cell, CF-45o cell	Homo sapiens	-
bronchial epithelium	-	Homo sapiens	-
bronchiolar epithelium	-	Homo sapiens	-
cystic fibrosis disease specific cell type	-	Homo sapiens	-
IB3-1 cell	-	Homo sapiens	-
tracheobronchial epithelial cell	-	Homo sapiens	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
ATP + H2O + Ca2+/cis	-	Homo sapiens	ADP + phosphate + Ca2+/trans	-	?

Synonyms

Synonyms	Comment	Organism
sarcoendoplasmic reticulum calcium ATPase	-	Homo sapiens
SERCA	-	Homo sapiens
SERCA2	lung isozyme	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)